IPO? In This Market?
News posting on September 17, 2008 | Related to Adnexus Therapeutics
Bristol-Myers continues with plans to spin off its nutritionals business.
Source: The Motley Fool
About Adnexus Therapeutics
Adnexus discovers and develops a novel, proprietary class of targeted biologics called Adnectinsô. We belie... Find out more
